Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: s. J Biol Chem. 2004. 279(17). 17508-17514. Find at Google Scholar.
Sheaffer, A.K., Mulherin, H.M., Chen, C., Dunaj, C.V., Lee, M.S., Franco, D.L., Campbell, J., Sit, S. Characterization of HCVreplicons resistant to inhibitors of NS3 protease activity. Proceedings of the 7th International Symposiu. 2004. . . Find at Google Scholar.
Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inh. Gastroenterology. 2007. 132(5). . Find at Google Scholar.
Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia. Characterization of resistance mutations against HCV ketoamide protease inhibitors.. Antiviral Res.. 2008. 77(3). 177-185. Find at Google Scholar.
Zhou Y, Bartels DJ, Hanzelka BL, Muh U, Wei Y, Chu HM, Tigges AM, Brennan DL, Rao BG, Swenson L, Kwo. Phenotypic characterization of Val36 resistant variants of hepatitis C virus NS3·4A serine protease.. Antimicrob Agents Chemother. 2008. 52. 110-120. Find at Google Scholar.
Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inh. Gastroenterology. 2007. 132(5). . Find at Google Scholar.
Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia. Characterization of resistance mutations against HCV ketoamide protease inhibitors.. Antiviral Res.. 2008. 77(3). 177-185. Find at Google Scholar.
Ralston R. . Development of resistance to boceprevir: observations from clinical trials . Program and abstracts of the 2nd Internationa. 2007. . . Find at Google Scholar.
Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C . Hepatology. 2007. 46(3). . Find at Google Scholar.
Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong . Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhib. J Infect Dis. . 2008. 15198(6). 800-807. Find at Google Scholar.
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong A. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely. J Virol. . 2013. 87(3). 1544-1553. Find at Google Scholar.
Barbotte L, Ahmed-Belkacem A, Chevaliez S, Soulier A, Hézode C, Wajcman H, Bartels DJ, Zhou Y, Ardzi. Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resista. Antimicrob Agents Chemother. 2010. 54(6). 2681-2683 . Find at Google Scholar.
Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receivi. PLoS One. 2012. 7(4). e34372. Find at Google Scholar.
Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, A. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. . Clin Infect Dis. . 2013. 57(2). 221-229. Find at Google Scholar.